Pharma & Healthcare
Global Anti-Parkinson Drugs Market Research Report 2024
- Jan 29, 24
- ID: 49812
- Pages: 83
- Figures: 166
- Views: 19
Anti-Parkinson Drugs are drugs used to treat Parkinson's disease.
The global Anti-Parkinson Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Parkinson Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Parkinson Drugs.
Report Scope
The Anti-Parkinson Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Parkinson Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Parkinson Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.
Segment by Type
Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Parkinson Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The global Anti-Parkinson Drugs market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Anti-Parkinson Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Anti-Parkinson Drugs.
Report Scope
The Anti-Parkinson Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Anti-Parkinson Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Anti-Parkinson Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
AbbVie
Mylan Laboratories
Valeant Pharmaceuticals
Novartis
GlaxoSmithKline
Zambon Pharmaceuticals
Pfizer, Inc.
Hoffmann-La Roche
Merck & Co.
Orion Pharma
UCB
Teva Pharmaceutical Industries Ltd.
Vertical Pharmaceuticals, LLC
ACADIA Pharmaceuticals Inc.
Segment by Type
Dopaminergic
Dopamine Agonists
Enzyme Inhibitors
Others
Segment by Application
Hospital Pharmacy
Retail Pharmacy
Online Stores
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Anti-Parkinson Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2019-2030)
2.2 Anti-Parkinson Drugs Growth Trends by Region
2.2.1 Global Anti-Parkinson Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-Parkinson Drugs Market Dynamics
2.3.1 Anti-Parkinson Drugs Industry Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2023
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2019-2030)
6.2 North America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-Parkinson Drugs Market Size by Country (2019-2024)
6.4 North America Anti-Parkinson Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2019-2030)
7.2 Europe Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-Parkinson Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-Parkinson Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2019-2030)
9.2 Latin America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Detail
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Detail
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Detail
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Detail
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Detail
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Detail
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Detail
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Detail
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Anti-Parkinson Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Dopaminergic
1.2.3 Dopamine Agonists
1.2.4 Enzyme Inhibitors
1.2.5 Others
1.3 Market by Application
1.3.1 Global Anti-Parkinson Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital Pharmacy
1.3.3 Retail Pharmacy
1.3.4 Online Stores
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Anti-Parkinson Drugs Market Perspective (2019-2030)
2.2 Anti-Parkinson Drugs Growth Trends by Region
2.2.1 Global Anti-Parkinson Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Anti-Parkinson Drugs Historic Market Size by Region (2019-2024)
2.2.3 Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030)
2.3 Anti-Parkinson Drugs Market Dynamics
2.3.1 Anti-Parkinson Drugs Industry Trends
2.3.2 Anti-Parkinson Drugs Market Drivers
2.3.3 Anti-Parkinson Drugs Market Challenges
2.3.4 Anti-Parkinson Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Anti-Parkinson Drugs Players by Revenue
3.1.1 Global Top Anti-Parkinson Drugs Players by Revenue (2019-2024)
3.1.2 Global Anti-Parkinson Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Anti-Parkinson Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Anti-Parkinson Drugs Revenue
3.4 Global Anti-Parkinson Drugs Market Concentration Ratio
3.4.1 Global Anti-Parkinson Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Anti-Parkinson Drugs Revenue in 2023
3.5 Anti-Parkinson Drugs Key Players Head office and Area Served
3.6 Key Players Anti-Parkinson Drugs Product Solution and Service
3.7 Date of Enter into Anti-Parkinson Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Anti-Parkinson Drugs Breakdown Data by Type
4.1 Global Anti-Parkinson Drugs Historic Market Size by Type (2019-2024)
4.2 Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030)
5 Anti-Parkinson Drugs Breakdown Data by Application
5.1 Global Anti-Parkinson Drugs Historic Market Size by Application (2019-2024)
5.2 Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Anti-Parkinson Drugs Market Size (2019-2030)
6.2 North America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Anti-Parkinson Drugs Market Size by Country (2019-2024)
6.4 North America Anti-Parkinson Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Anti-Parkinson Drugs Market Size (2019-2030)
7.2 Europe Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Anti-Parkinson Drugs Market Size by Country (2019-2024)
7.4 Europe Anti-Parkinson Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Anti-Parkinson Drugs Market Size (2019-2030)
8.2 Asia-Pacific Anti-Parkinson Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Anti-Parkinson Drugs Market Size (2019-2030)
9.2 Latin America Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024)
9.4 Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Anti-Parkinson Drugs Market Size (2019-2030)
10.2 Middle East & Africa Anti-Parkinson Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 AbbVie
11.1.1 AbbVie Company Detail
11.1.2 AbbVie Business Overview
11.1.3 AbbVie Anti-Parkinson Drugs Introduction
11.1.4 AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.1.5 AbbVie Recent Development
11.2 Mylan Laboratories
11.2.1 Mylan Laboratories Company Detail
11.2.2 Mylan Laboratories Business Overview
11.2.3 Mylan Laboratories Anti-Parkinson Drugs Introduction
11.2.4 Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.2.5 Mylan Laboratories Recent Development
11.3 Valeant Pharmaceuticals
11.3.1 Valeant Pharmaceuticals Company Detail
11.3.2 Valeant Pharmaceuticals Business Overview
11.3.3 Valeant Pharmaceuticals Anti-Parkinson Drugs Introduction
11.3.4 Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.3.5 Valeant Pharmaceuticals Recent Development
11.4 Novartis
11.4.1 Novartis Company Detail
11.4.2 Novartis Business Overview
11.4.3 Novartis Anti-Parkinson Drugs Introduction
11.4.4 Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.4.5 Novartis Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Anti-Parkinson Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Zambon Pharmaceuticals
11.6.1 Zambon Pharmaceuticals Company Detail
11.6.2 Zambon Pharmaceuticals Business Overview
11.6.3 Zambon Pharmaceuticals Anti-Parkinson Drugs Introduction
11.6.4 Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.6.5 Zambon Pharmaceuticals Recent Development
11.7 Pfizer, Inc.
11.7.1 Pfizer, Inc. Company Detail
11.7.2 Pfizer, Inc. Business Overview
11.7.3 Pfizer, Inc. Anti-Parkinson Drugs Introduction
11.7.4 Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.7.5 Pfizer, Inc. Recent Development
11.8 Hoffmann-La Roche
11.8.1 Hoffmann-La Roche Company Detail
11.8.2 Hoffmann-La Roche Business Overview
11.8.3 Hoffmann-La Roche Anti-Parkinson Drugs Introduction
11.8.4 Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.8.5 Hoffmann-La Roche Recent Development
11.9 Merck & Co.
11.9.1 Merck & Co. Company Detail
11.9.2 Merck & Co. Business Overview
11.9.3 Merck & Co. Anti-Parkinson Drugs Introduction
11.9.4 Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.9.5 Merck & Co. Recent Development
11.10 Orion Pharma
11.10.1 Orion Pharma Company Detail
11.10.2 Orion Pharma Business Overview
11.10.3 Orion Pharma Anti-Parkinson Drugs Introduction
11.10.4 Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.10.5 Orion Pharma Recent Development
11.11 UCB
11.11.1 UCB Company Detail
11.11.2 UCB Business Overview
11.11.3 UCB Anti-Parkinson Drugs Introduction
11.11.4 UCB Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.11.5 UCB Recent Development
11.12 Teva Pharmaceutical Industries Ltd.
11.12.1 Teva Pharmaceutical Industries Ltd. Company Detail
11.12.2 Teva Pharmaceutical Industries Ltd. Business Overview
11.12.3 Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Introduction
11.12.4 Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.12.5 Teva Pharmaceutical Industries Ltd. Recent Development
11.13 Vertical Pharmaceuticals, LLC
11.13.1 Vertical Pharmaceuticals, LLC Company Detail
11.13.2 Vertical Pharmaceuticals, LLC Business Overview
11.13.3 Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Introduction
11.13.4 Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.13.5 Vertical Pharmaceuticals, LLC Recent Development
11.14 ACADIA Pharmaceuticals Inc.
11.14.1 ACADIA Pharmaceuticals Inc. Company Detail
11.14.2 ACADIA Pharmaceuticals Inc. Business Overview
11.14.3 ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Introduction
11.14.4 ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024)
11.14.5 ACADIA Pharmaceuticals Inc. Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of Tables
Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Dopaminergic
Table 3. Key Players of Dopamine Agonists
Table 4. Key Players of Enzyme Inhibitors
Table 5. Key Players of Others
Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Anti-Parkinson Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Anti-Parkinson Drugs Market Share by Region (2019-2024)
Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Anti-Parkinson Drugs Market Share by Region (2025-2030)
Table 12. Anti-Parkinson Drugs Market Trends
Table 13. Anti-Parkinson Drugs Market Drivers
Table 14. Anti-Parkinson Drugs Market Challenges
Table 15. Anti-Parkinson Drugs Market Restraints
Table 16. Global Anti-Parkinson Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Anti-Parkinson Drugs Market Share by Players (2019-2024)
Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
Table 23. Date of Enter into Anti-Parkinson Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Anti-Parkinson Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Detail
Table 49. AbbVie Business Overview
Table 50. AbbVie Anti-Parkinson Drugs Product
Table 51. AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. Mylan Laboratories Company Detail
Table 54. Mylan Laboratories Business Overview
Table 55. Mylan Laboratories Anti-Parkinson Drugs Product
Table 56. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 57. Mylan Laboratories Recent Development
Table 58. Valeant Pharmaceuticals Company Detail
Table 59. Valeant Pharmaceuticals Business Overview
Table 60. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
Table 61. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 62. Valeant Pharmaceuticals Recent Development
Table 63. Novartis Company Detail
Table 64. Novartis Business Overview
Table 65. Novartis Anti-Parkinson Drugs Product
Table 66. Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. GlaxoSmithKline Company Detail
Table 69. GlaxoSmithKline Business Overview
Table 70. GlaxoSmithKline Anti-Parkinson Drugs Product
Table 71. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 72. GlaxoSmithKline Recent Development
Table 73. Zambon Pharmaceuticals Company Detail
Table 74. Zambon Pharmaceuticals Business Overview
Table 75. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
Table 76. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 77. Zambon Pharmaceuticals Recent Development
Table 78. Pfizer, Inc. Company Detail
Table 79. Pfizer, Inc. Business Overview
Table 80. Pfizer, Inc. Anti-Parkinson Drugs Product
Table 81. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 82. Pfizer, Inc. Recent Development
Table 83. Hoffmann-La Roche Company Detail
Table 84. Hoffmann-La Roche Business Overview
Table 85. Hoffmann-La Roche Anti-Parkinson Drugs Product
Table 86. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 87. Hoffmann-La Roche Recent Development
Table 88. Merck & Co. Company Detail
Table 89. Merck & Co. Business Overview
Table 90. Merck & Co. Anti-Parkinson Drugs Product
Table 91. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 92. Merck & Co. Recent Development
Table 93. Orion Pharma Company Detail
Table 94. Orion Pharma Business Overview
Table 95. Orion Pharma Anti-Parkinson Drugs Product
Table 96. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 97. Orion Pharma Recent Development
Table 98. UCB Company Detail
Table 99. UCB Business Overview
Table 100. UCB Anti-Parkinson Drugs Product
Table 101. UCB Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 102. UCB Recent Development
Table 103. Teva Pharmaceutical Industries Ltd. Company Detail
Table 104. Teva Pharmaceutical Industries Ltd. Business Overview
Table 105. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product
Table 106. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Ltd. Recent Development
Table 108. Vertical Pharmaceuticals, LLC Company Detail
Table 109. Vertical Pharmaceuticals, LLC Business Overview
Table 110. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product
Table 111. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 112. Vertical Pharmaceuticals, LLC Recent Development
Table 113. ACADIA Pharmaceuticals Inc. Company Detail
Table 114. ACADIA Pharmaceuticals Inc. Business Overview
Table 115. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product
Table 116. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 117. ACADIA Pharmaceuticals Inc. Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-Parkinson Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Anti-Parkinson Drugs Market Share by Type: 2023 VS 2030
Figure 3. Dopaminergic Features
Figure 4. Dopamine Agonists Features
Figure 5. Enzyme Inhibitors Features
Figure 6. Others Features
Figure 7. Global Anti-Parkinson Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Anti-Parkinson Drugs Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Online Stores Case Studies
Figure 12. Anti-Parkinson Drugs Report Years Considered
Figure 13. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Anti-Parkinson Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Anti-Parkinson Drugs Market Share by Players in 2023
Figure 17. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2023
Figure 19. North America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 21. United States Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 25. Germany Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2019-2030)
Figure 33. China Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 48. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 49. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 52. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 53. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 54. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 55. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 56. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 57. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 58. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 59. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 60. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Table 1. Global Anti-Parkinson Drugs Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Dopaminergic
Table 3. Key Players of Dopamine Agonists
Table 4. Key Players of Enzyme Inhibitors
Table 5. Key Players of Others
Table 6. Global Anti-Parkinson Drugs Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Anti-Parkinson Drugs Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Anti-Parkinson Drugs Market Share by Region (2019-2024)
Table 10. Global Anti-Parkinson Drugs Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Anti-Parkinson Drugs Market Share by Region (2025-2030)
Table 12. Anti-Parkinson Drugs Market Trends
Table 13. Anti-Parkinson Drugs Market Drivers
Table 14. Anti-Parkinson Drugs Market Challenges
Table 15. Anti-Parkinson Drugs Market Restraints
Table 16. Global Anti-Parkinson Drugs Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Anti-Parkinson Drugs Market Share by Players (2019-2024)
Table 18. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
Table 19. Ranking of Global Top Anti-Parkinson Drugs Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Anti-Parkinson Drugs Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Anti-Parkinson Drugs Product Solution and Service
Table 23. Date of Enter into Anti-Parkinson Drugs Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Anti-Parkinson Drugs Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Anti-Parkinson Drugs Revenue Market Share by Type (2019-2024)
Table 27. Global Anti-Parkinson Drugs Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Anti-Parkinson Drugs Revenue Market Share by Type (2025-2030)
Table 29. Global Anti-Parkinson Drugs Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Anti-Parkinson Drugs Revenue Market Share by Application (2019-2024)
Table 31. Global Anti-Parkinson Drugs Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Anti-Parkinson Drugs Revenue Market Share by Application (2025-2030)
Table 33. North America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Anti-Parkinson Drugs Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Anti-Parkinson Drugs Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Anti-Parkinson Drugs Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Anti-Parkinson Drugs Market Size by Country (2025-2030) & (US$ Million)
Table 48. AbbVie Company Detail
Table 49. AbbVie Business Overview
Table 50. AbbVie Anti-Parkinson Drugs Product
Table 51. AbbVie Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 52. AbbVie Recent Development
Table 53. Mylan Laboratories Company Detail
Table 54. Mylan Laboratories Business Overview
Table 55. Mylan Laboratories Anti-Parkinson Drugs Product
Table 56. Mylan Laboratories Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 57. Mylan Laboratories Recent Development
Table 58. Valeant Pharmaceuticals Company Detail
Table 59. Valeant Pharmaceuticals Business Overview
Table 60. Valeant Pharmaceuticals Anti-Parkinson Drugs Product
Table 61. Valeant Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 62. Valeant Pharmaceuticals Recent Development
Table 63. Novartis Company Detail
Table 64. Novartis Business Overview
Table 65. Novartis Anti-Parkinson Drugs Product
Table 66. Novartis Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 67. Novartis Recent Development
Table 68. GlaxoSmithKline Company Detail
Table 69. GlaxoSmithKline Business Overview
Table 70. GlaxoSmithKline Anti-Parkinson Drugs Product
Table 71. GlaxoSmithKline Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 72. GlaxoSmithKline Recent Development
Table 73. Zambon Pharmaceuticals Company Detail
Table 74. Zambon Pharmaceuticals Business Overview
Table 75. Zambon Pharmaceuticals Anti-Parkinson Drugs Product
Table 76. Zambon Pharmaceuticals Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 77. Zambon Pharmaceuticals Recent Development
Table 78. Pfizer, Inc. Company Detail
Table 79. Pfizer, Inc. Business Overview
Table 80. Pfizer, Inc. Anti-Parkinson Drugs Product
Table 81. Pfizer, Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 82. Pfizer, Inc. Recent Development
Table 83. Hoffmann-La Roche Company Detail
Table 84. Hoffmann-La Roche Business Overview
Table 85. Hoffmann-La Roche Anti-Parkinson Drugs Product
Table 86. Hoffmann-La Roche Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 87. Hoffmann-La Roche Recent Development
Table 88. Merck & Co. Company Detail
Table 89. Merck & Co. Business Overview
Table 90. Merck & Co. Anti-Parkinson Drugs Product
Table 91. Merck & Co. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 92. Merck & Co. Recent Development
Table 93. Orion Pharma Company Detail
Table 94. Orion Pharma Business Overview
Table 95. Orion Pharma Anti-Parkinson Drugs Product
Table 96. Orion Pharma Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 97. Orion Pharma Recent Development
Table 98. UCB Company Detail
Table 99. UCB Business Overview
Table 100. UCB Anti-Parkinson Drugs Product
Table 101. UCB Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 102. UCB Recent Development
Table 103. Teva Pharmaceutical Industries Ltd. Company Detail
Table 104. Teva Pharmaceutical Industries Ltd. Business Overview
Table 105. Teva Pharmaceutical Industries Ltd. Anti-Parkinson Drugs Product
Table 106. Teva Pharmaceutical Industries Ltd. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 107. Teva Pharmaceutical Industries Ltd. Recent Development
Table 108. Vertical Pharmaceuticals, LLC Company Detail
Table 109. Vertical Pharmaceuticals, LLC Business Overview
Table 110. Vertical Pharmaceuticals, LLC Anti-Parkinson Drugs Product
Table 111. Vertical Pharmaceuticals, LLC Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 112. Vertical Pharmaceuticals, LLC Recent Development
Table 113. ACADIA Pharmaceuticals Inc. Company Detail
Table 114. ACADIA Pharmaceuticals Inc. Business Overview
Table 115. ACADIA Pharmaceuticals Inc. Anti-Parkinson Drugs Product
Table 116. ACADIA Pharmaceuticals Inc. Revenue in Anti-Parkinson Drugs Business (2019-2024) & (US$ Million)
Table 117. ACADIA Pharmaceuticals Inc. Recent Development
Table 118. Research Programs/Design for This Report
Table 119. Key Data Information from Secondary Sources
Table 120. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Anti-Parkinson Drugs Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Anti-Parkinson Drugs Market Share by Type: 2023 VS 2030
Figure 3. Dopaminergic Features
Figure 4. Dopamine Agonists Features
Figure 5. Enzyme Inhibitors Features
Figure 6. Others Features
Figure 7. Global Anti-Parkinson Drugs Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Anti-Parkinson Drugs Market Share by Application: 2023 VS 2030
Figure 9. Hospital Pharmacy Case Studies
Figure 10. Retail Pharmacy Case Studies
Figure 11. Online Stores Case Studies
Figure 12. Anti-Parkinson Drugs Report Years Considered
Figure 13. Global Anti-Parkinson Drugs Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 14. Global Anti-Parkinson Drugs Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 15. Global Anti-Parkinson Drugs Market Share by Region: 2023 VS 2030
Figure 16. Global Anti-Parkinson Drugs Market Share by Players in 2023
Figure 17. Global Top Anti-Parkinson Drugs Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Anti-Parkinson Drugs as of 2023)
Figure 18. The Top 10 and 5 Players Market Share by Anti-Parkinson Drugs Revenue in 2023
Figure 19. North America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. North America Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 21. United States Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Canada Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. Europe Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 25. Germany Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. France Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. U.K. Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Italy Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Russia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Nordic Countries Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Asia-Pacific Anti-Parkinson Drugs Market Share by Region (2019-2030)
Figure 33. China Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Japan Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. South Korea Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Southeast Asia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. India Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Australia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Latin America Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 41. Mexico Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Brazil Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Middle East & Africa Anti-Parkinson Drugs Market Share by Country (2019-2030)
Figure 45. Turkey Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Saudi Arabia Anti-Parkinson Drugs Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 47. AbbVie Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 48. Mylan Laboratories Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 49. Valeant Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 50. Novartis Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 51. GlaxoSmithKline Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 52. Zambon Pharmaceuticals Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 53. Pfizer, Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 54. Hoffmann-La Roche Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 55. Merck & Co. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 56. Orion Pharma Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 57. UCB Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 58. Teva Pharmaceutical Industries Ltd. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 59. Vertical Pharmaceuticals, LLC Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 60. ACADIA Pharmaceuticals Inc. Revenue Growth Rate in Anti-Parkinson Drugs Business (2019-2024)
Figure 61. Bottom-up and Top-down Approaches for This Report
Figure 62. Data Triangulation
Figure 63. Key Executives Interviewed
Our team would be happy to assist you with your queries.
About us
Accurate data, The latest market trends, And deeper research directions.
Our sole purpose is to provide a basis for leaders in all walks of life to make more appropriate decisions, to help companies solve existing problems and achieve business goals
Latest reports
DigitalBroadcast and Cinematography Cameras Lease - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Mobile and Web Event Analytics - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Business Information - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Sep 18, 24
Useful links
Our Contacts
Room 2306, T6 Fuxing World Financial Center, Kaifu District, Changsha, Hunan, China
(+86) 159 1069 5232